We don’t know the rate at which Republicans and Democrats will defect, how independents will break, or how early voting ...

We don’t know the rate at which Republicans and Democrats will defect, how independents will break, or how early voting patterns will change ...

Big Pharma is in federal appeals court making the absurd argument that Medicare shouldn’t be able to negotiate drug prices, a ...

Plus, debunking the myth of noncitizen voters, and assessing whether multicultural democracy can survive in America — all in ...

Federal law prohibits them from voting, and there’s no evidence that they’re doing so in any numbers that could sway ...

The Vice President. a veteran prosecutor. still has time for a great closing argument, but Harris needs to hone her summation ...

The late Ronald Tataki’s history of multicultural America roiled academic waters 30 years ago. It turned out to be prescient ...

Big Pharma is in federal appeals court making the absurd argument that Medicare shouldn’t be able to negotiate drug prices, a power given it by the Inflation Reduction Act.

Plus, why Trump is avoiding mainstream media, why Democrats should give the Green Party nominee the silent treatment, and the ...

The GOP nominee is using the campaign's final days to aim at a narrower segment of the electorate while Harris goes wider.

The infamous 887-page policy manual linked to Donald Trump and J.D. Vance aims to take Ron DeSantis’s war against liberal ...

Plus, debunking the myth of noncitizen voters, and assessing whether multicultural democracy can survive in America — all in the October 22, 2024 newsletter.